Heymach J, et al. A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.06.
Europese consensusaanbevelingen voor oligo-gemetastaseerd slokdarm-/maagcarcinoom
feb 2024 | Maag-darm-leveroncologie